KOSDAQFood & Beverage318010

Pharmsville

₩3,330▲ 2.30%2026-11-18 close
Market Cap
₩26.4B
Turnover
₩7,399,505
Volume
2.3K
Shares out.
7.9M
PER
13.4×
PBR
0.4×
EPS
₩246
Dividend Yield
6.06%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Pharmsville: Mixed Profit Trend Amid Falling Sales

Pharmsville's sales have declined for four straight quarters, yet its operating loss in the third quarter of 2026 narrowed from a year earlier, and its debt load remains small.

  1. 1

    Annual sales fell from KRW 26.1 billion in 2022 to KRW 12.7 billion in 2025, declining for three consecutive years from 2023 to 2025.

  2. 2

    The operating loss swung to KRW 258 million in 2024 and widened to KRW 673 million in 2025, making it a loss in both years.

  3. 3

    Net income attributable to controlling shareholders rose 82.5% to KRW 2.89 billion in 2025, while operating profit fell and the company cited higher financial income as the reason net profit increased.

  4. 4

    Third-quarter 2026 sales were KRW 2.06 billion, down 38.8% from a year earlier, while the operating loss narrowed to KRW 64.89 million.

  5. 5

    At the end of 2025, total equity stood at KRW 66.5 billion and total liabilities at KRW 1.95 billion, a liabilities-to-equity ratio of 2.9%.

02

Business structure

Pharmsville develops, manufactures and distributes health functional foods, and it listed on KOSDAQ in October 2019. The company has built its business around its own brands, and a 2020 brokerage report said it holds about ten brands, including Appletree Kim Pharmacist and Devil Diet.

By product segment, immunity and antioxidant products accounted for 37% of sales in the second quarter of 2026, diet and inner beauty for 26%, joint health for 22%, nutritional supplements for 10%, and eye health for 5% (Butler data).

Because the classification has changed, direct comparison with segment shares in earlier years is difficult. Home shopping was the main distribution channel, accounting for 62% of sales in 2019 according to a 2020 report.

In 2021 the company said it had completed a listing agreement covering 140 E-Mart stores, and the 2020 government deregulation that allowed free sales of health functional foods in large supermarkets and department stores was cited as a factor behind wider distribution.

On the manufacturing side, a 2021 technical analysis report pointed to the construction of an in-house GMP-certified facility as a strengthening factor. A 2021 press report said the company had registered more than 100 overseas patents and trademarks.

In competition, listed food-sector peers such as CJ Cheiljedang, Orion and Nongshim have far larger food sales than Pharmsville. Pharmsville is a small and mid-sized health functional food brand company that depends on home shopping programming and brand recognition.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.4B-₩100M−3.5%
2025Q4₩3B-₩400M−11.9%
2026Q1₩2.5B-₩55,278,439−2.2%
2026Q2₩2.4B-₩200M−6.8%
2026Q3₩2.1B-₩64,885,658−3.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩26.1B₩4.1B₩4.1B15.6%6.5%19.4%
2023₩21.4B₩1.6B₩3.3B7.6%5.2%11.3%
2024₩16.7B-₩300M₩1.6B−1.5%2.5%3.9%
2025₩12.7B-₩700M₩2.9B−5.3%4.3%2.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results show falling sales feeding into weaker profit. Consolidated sales dropped from KRW 26.1 billion in 2022 to KRW 21.4 billion in 2023 (down 18.1% year on year), KRW 16.7 billion in 2024 (down 21.8%), and KRW 12.7 billion in 2025 (down 23.9%), with 2022 the largest year in the 2022 to 2025 span.

The operating margin fell from 15.6% in 2022 to 7.6% in 2023, -1.5% in 2024 and -5.3% in 2025. Operating profit declined from KRW 4.06 billion in 2022 to KRW 1.63 billion in 2023 (down 59.8%), and the company swung to an operating loss of KRW 258 million in 2024 before the loss widened to KRW 673 million in 2025.

In its 2025 disclosure, published on February 10, 2026, the company said operating profit fell because sales declined and cost of sales rose.

Net income attributable to controlling shareholders went from KRW 4.06 billion in 2022 to KRW 3.31 billion in 2023 and KRW 1.58 billion in 2024, then rose to KRW 2.89 billion in 2025 (up 82.5%).

Net income including non-controlling interests was KRW 2.9 billion in 2025, and the company attributed the increase to higher financial income. The 2025 profit recovery therefore leaned on non-operating income rather than operating improvement.

Operating cash flow moved from negative KRW 347 million in 2024 to KRW 1.89 billion in 2025.

Quarterly sales were KRW 3.37 billion in the third quarter of 2025, KRW 2.96 billion in the fourth quarter (down 12.1% from the prior quarter), KRW 2.49 billion in the first quarter of 2026 (down 16.1%), KRW 2.38 billion in the second quarter (down 4.2%) and KRW 2.06 billion in the third quarter (down 13.5%), a decline across four consecutive quarters.

The operating loss has persisted for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026.

Net income attributable to controlling shareholders rose to KRW 824 million in the fourth quarter of 2025 and KRW 1.2 billion in the first quarter of 2026, then fell to KRW 466 million in the second quarter and turned into a net loss of KRW 600 million in the third quarter of 2026. Over the last four quarters, the total was KRW 1.9 billion.

05

Industry analysis

The health functional food market is strongly shaped by distribution regulation and sales channels.

In 2020 the government allowed free sales of health functional foods at large supermarkets and department stores, which lowered the barrier to offline distribution, and Pharmsville expanded its store presence in the years that followed.

However, home shopping as its main channel means sales are sensitive to changes in broadcast scheduling and channel policy. Compared with larger listed food-sector companies such as CJ Cheiljedang, Orion and Nongshim, Pharmsville has much smaller sales and a narrower business focused on health functional foods.

Large food companies hold advantages in distribution networks and raw material procurement, while Pharmsville has relied on its own brands and home shopping programming. The quarterly sales decline in 2026 is consistent with the volatility that comes from this channel dependence.

Apart from movements in the sector index, companies with small market capitalizations often see larger trading swings. When assessing its position within the sector, sales scale, channel concentration and in-house production capacity should be considered together.

06

Outlook

The direction the company has stated is a rebound through the development of new materials. A financial information site summarizing the first quarter of 2026 described the company as seeking a recovery by developing new materials despite falling sales.

However, the sales contribution and timing of the new materials do not appear in the disclosed figures.

The first point to watch is whether fourth-quarter 2026 sales break the four-quarter decline; third-quarter 2026 sales of KRW 2.06 billion were below the KRW 2.96 billion of the fourth quarter of 2025, so the decline is still ongoing.

The operating loss narrowed to KRW 64.89 million in the third quarter of 2026, but it had widened to KRW 162 million in the second quarter, so quarterly results have moved up and down.

Net income attributable to controlling shareholders turned into a KRW 600 million net loss in the third quarter of 2026, so how much financial gains and losses affect the net income trend is the next point to verify.

The 2026 fiscal year closes at the end of December, and results will be reported in the annual report, which carries a statutory filing deadline at the end of March 2027. In that report, it can be checked whether full-year 2026 sales and the operating margin continue the losses seen in 2024 and 2025. Decisions on dividends are made when financial statements are approved at the annual general meeting.

07

Valuation

PER
13.4×
PBR
0.4×
ROE
2.9%
EPS
₩246
BPS
₩8,556
Dividend per share
₩200

Valuation reads more sensibly through assets and dividends than through earnings multiples, given the recent operating trend. The price-to-book ratio sits well below 1x, and market capitalization is below total equity at the end of 2025.

The dividend yield is higher than the average of the KOSDAQ food and tobacco sector. Earnings-based multiples are harder to interpret, because net income attributable to controlling shareholders totaled KRW 1.9 billion over the last four quarters and turned into a net loss in the third quarter of 2026.

Since net income in 2025 was supported by higher financial income, earnings-based multiples need to be split between operating and non-operating profit. Comparisons with past valuation bands also depend on the date chosen because they move with the share price, so the comparison point should be stated clearly.

A low multiple relative to net assets reflects the gap between asset value and current earnings; it does not by itself indicate direction.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Narrowing operating loss

The operating loss in the third quarter of 2026 was KRW 64.89 million, a narrower loss than a year earlier. The first-quarter 2026 operating loss of KRW 55.28 million was also smaller than the KRW 351 million loss of the fourth quarter of 2025.

Bulls read the quarters with smaller losses as a sign of a steadier profit structure, even though losses have continued.

Strong balance sheet

Total equity at the end of 2025 was KRW 66.5 billion, with total liabilities of KRW 1.95 billion and a liabilities-to-equity ratio of 2.9%. Operating cash flow in 2025 was KRW 1.89 billion, turning positive from negative KRW 347 million in 2024. Bulls argue that with little borrowing, financial risk stays limited even if operating losses continue.

Shareholder returns and new materials

A financial information site summarizing the first quarter of 2026 described the company as seeking a rebound through new materials. Bulls point to the possibility that if the sales decline stops and new materials contribute to results, the business structure could change.

09

Bear factors

Four straight quarters of sales decline

Sales have declined for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026. Third-quarter 2026 sales of KRW 2.06 billion were down 38.8% from a year earlier.

Annual sales fell from KRW 26.1 billion in 2022 to KRW 12.7 billion in 2025, which bears see as the biggest concern about a continuing contraction in scale.

Two years of operating losses and margin erosion

The company recorded operating losses in both 2024 and 2025, and the operating margin was -5.3% in 2025. The company said operating profit declined because sales fell and cost of sales rose. Bears point to the drop in operating margin from 15.6% in 2022 to -5.3% in 2025 as the core evidence.

Net income leaning on non-operating gains

The 2025 increase in net income was supported by higher financial income. Net income attributable to controlling shareholders totaled KRW 1.9 billion over the last four quarters, and the third quarter of 2026 turned into a KRW 600 million net loss. Bears see profit that leans on non-operating items as less durable.

10

Risk factors

Channel concentration

Results can depend heavily on home shopping programming and channel policy. A 2020 report put the home shopping share of 2019 sales at 62%, so channel concentration is a long-standing feature. A reduction in airtime or changes in terms with a major channel could affect sales quickly.

Regulation and policy

Distribution and advertising rules for health functional foods change with policy. The 2020 relaxation that allowed free sales in large supermarkets and department stores was an opportunity, but renewed tightening could reduce the benefit of wider distribution. Changes to functional claim standards could also affect product launch timing.

Cost and cash flow volatility

The company said cost of sales rose in 2025 and reduced operating profit. If higher costs cannot be passed on to selling prices, losses could widen. Operating cash flow was negative in 2024, so whether it stays positive on a steady basis is a key point to monitor.

11

What to watch next

  1. Late December 2026

    The 2026 fiscal year closes. Whether fourth-quarter sales continue the four-quarter decline is the first variable for full-year results.

  2. Late March 2027

    This is the statutory deadline for the 2026 annual report. It shows whether the operating margin moves out of the 2024 and 2025 loss pattern and how fourth-quarter profit and loss turned out.

  3. Around March 2027 annual general meeting

    Financial statements are approved and dividend decisions are made at this meeting. The 2026 meeting was held on March 26, so agenda items including the dividend decision are the points to check.

  4. Around May 15, 2027

    This is the approximate filing date for the first-quarter 2027 report. Compared with KRW 2.49 billion in sales and KRW 1.2 billion in net income attributable to controlling shareholders in the first quarter of 2026, it will show whether the sales decline has stopped and whether profit came from operations.

12

Overall view

Pharmsville's core business shows clear weakness in the form of falling sales and continued losses. Annual sales declined from KRW 26.1 billion in 2022 to KRW 12.7 billion in 2025, and the operating margin was -5.3% in 2025.

Quarterly sales fell for four consecutive quarters in 2026, and net income attributable to controlling shareholders turned into a loss in the third quarter. On the other side, the operating loss narrowed in the third quarter of 2026 from a year earlier, and operating cash flow turned positive in 2025.

A liabilities-to-equity ratio of 2.9% and total equity of KRW 66.5 billion could serve as a cushion while the core business recovers. However, the 2025 net income recovery was supported by higher financial income, so the quality of earnings is mixed.

The key item to watch is whether the rebound effort the company describes through new materials translates into sales. The next checkpoint is the 2026 annual report, where the benchmarks are whether the annual sales decline continues and whether the operating margin moves out of the loss range.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.fnguide.com
  2. butler.works
  3. news.nate.com
  4. ssl.pstatic.net
  5. m.news.nate.com
  6. edaily.co.kr
  7. edaily.co.kr
  8. edaily.co.kr
  9. edaily.co.kr
  10. the-stock.kr
  11. news.nate.com
  12. judal.co.kr
  13. judal.co.kr
  14. judal.co.kr
  15. judal.co.kr
  16. judal.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis